Učitavanje...
Combating acquired resistance to tyrosine kinase inhibitors in lung cancer
The prospective identification and therapeutic targeting of oncogenic tyrosine kinases with tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of patients with non-small cell lung cancer (NSCLC). TKI therapy frequently induces dramatic clinical responses in molecularly defined cohort...
Spremljeno u:
| Izdano u: | Am Soc Clin Oncol Educ Book |
|---|---|
| Glavni autor: | |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2015
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4734636/ https://ncbi.nlm.nih.gov/pubmed/25993168 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14694/EdBook_AM.2015.35.e165 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|